多cpg线性回归模型准确预测紫杉醇和多西紫杉醇在癌细胞中的活性。

2区 医学 Q1 Medicine
Manny D Bacolod, Paul B Fisher, Francis Barany
{"title":"多cpg线性回归模型准确预测紫杉醇和多西紫杉醇在癌细胞中的活性。","authors":"Manny D Bacolod,&nbsp;Paul B Fisher,&nbsp;Francis Barany","doi":"10.1016/bs.acr.2022.12.005","DOIUrl":null,"url":null,"abstract":"<p><p>The microtubule-targeting paclitaxel (PTX) and docetaxel (DTX) are widely used chemotherapeutic agents. However, the dysregulation of apoptotic processes, microtubule-binding proteins, and multi-drug resistance efflux and influx proteins can alter the efficacy of taxane drugs. In this review, we have created multi-CpG linear regression models to predict the activities of PTX and DTX drugs through the integration of publicly available pharmacological and genome-wide molecular profiling datasets generated using hundreds of cancer cell lines of diverse tissue of origin. Our findings indicate that linear regression models based on CpG methylation levels can predict PTX and DTX activities (log-fold change in viability relative to DMSO) with high precision. For example, a 287-CpG model predicts PTX activity at R<sup>2</sup> of 0.985 among 399 cell lines. Just as precise (R<sup>2</sup>=0.996) is a 342-CpG model for predicting DTX activity in 390 cell lines. However, our predictive models, which employ a combination of mRNA expression and mutation as input variables, are less accurate compared to the CpG-based models. While a 290 mRNA/mutation model was able to predict PTX activity with R<sup>2</sup> of 0.830 (for 546 cell lines), a 236 mRNA/mutation model could calculate DTX activity at R<sup>2</sup> of 0.751 (for 531 cell lines). The CpG-based models restricted to lung cancer cell lines were also highly predictive (R<sup>2</sup>≥0.980) for PTX (74 CpGs, 88 cell lines) and DTX (58 CpGs, 83 cell lines). The underlying molecular biology behind taxane activity/resistance is evident in these models. Indeed, many of the genes represented in PTX or DTX CpG-based models have functionalities related to apoptosis (e.g., ACIN1, TP73, TNFRSF10B, DNASE1, DFFB, CREB1, BNIP3), and mitosis/microtubules (e.g., MAD1L1, ANAPC2, EML4, PARP3, CCT6A, JAKMIP1). Also represented are genes involved in epigenetic regulation (HDAC4, DNMT3B, and histone demethylases KDM4B, KDM4C, KDM2B, and KDM7A), and those that have never been previously linked to taxane activity (DIP2C, PTPRN2, TTC23, SHANK2). In summary, it is possible to accurately predict taxane activity in cell lines based entirely on methylation at multiple CpG sites.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"158 ","pages":"233-292"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines.\",\"authors\":\"Manny D Bacolod,&nbsp;Paul B Fisher,&nbsp;Francis Barany\",\"doi\":\"10.1016/bs.acr.2022.12.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The microtubule-targeting paclitaxel (PTX) and docetaxel (DTX) are widely used chemotherapeutic agents. However, the dysregulation of apoptotic processes, microtubule-binding proteins, and multi-drug resistance efflux and influx proteins can alter the efficacy of taxane drugs. In this review, we have created multi-CpG linear regression models to predict the activities of PTX and DTX drugs through the integration of publicly available pharmacological and genome-wide molecular profiling datasets generated using hundreds of cancer cell lines of diverse tissue of origin. Our findings indicate that linear regression models based on CpG methylation levels can predict PTX and DTX activities (log-fold change in viability relative to DMSO) with high precision. For example, a 287-CpG model predicts PTX activity at R<sup>2</sup> of 0.985 among 399 cell lines. Just as precise (R<sup>2</sup>=0.996) is a 342-CpG model for predicting DTX activity in 390 cell lines. However, our predictive models, which employ a combination of mRNA expression and mutation as input variables, are less accurate compared to the CpG-based models. While a 290 mRNA/mutation model was able to predict PTX activity with R<sup>2</sup> of 0.830 (for 546 cell lines), a 236 mRNA/mutation model could calculate DTX activity at R<sup>2</sup> of 0.751 (for 531 cell lines). The CpG-based models restricted to lung cancer cell lines were also highly predictive (R<sup>2</sup>≥0.980) for PTX (74 CpGs, 88 cell lines) and DTX (58 CpGs, 83 cell lines). The underlying molecular biology behind taxane activity/resistance is evident in these models. Indeed, many of the genes represented in PTX or DTX CpG-based models have functionalities related to apoptosis (e.g., ACIN1, TP73, TNFRSF10B, DNASE1, DFFB, CREB1, BNIP3), and mitosis/microtubules (e.g., MAD1L1, ANAPC2, EML4, PARP3, CCT6A, JAKMIP1). Also represented are genes involved in epigenetic regulation (HDAC4, DNMT3B, and histone demethylases KDM4B, KDM4C, KDM2B, and KDM7A), and those that have never been previously linked to taxane activity (DIP2C, PTPRN2, TTC23, SHANK2). In summary, it is possible to accurately predict taxane activity in cell lines based entirely on methylation at multiple CpG sites.</p>\",\"PeriodicalId\":50875,\"journal\":{\"name\":\"Advances in Cancer Research\",\"volume\":\"158 \",\"pages\":\"233-292\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.acr.2022.12.005\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acr.2022.12.005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

微管靶向紫杉醇(PTX)和多西紫杉醇(DTX)是目前广泛应用的化疗药物。然而,凋亡过程、微管结合蛋白、多药耐药外排和内流蛋白的失调可改变紫杉烷类药物的疗效。在这篇综述中,我们建立了多cpg线性回归模型,通过整合公开可用的药理学和全基因组分子分析数据集来预测PTX和DTX药物的活性,这些数据集来自数百种不同来源组织的癌细胞系。研究结果表明,基于CpG甲基化水平的线性回归模型可以高精度地预测PTX和DTX活性(相对于DMSO活力的对数倍变化)。例如,一个287-CpG模型预测399个细胞系的PTX活性R2为0.985。同样精确(R2=0.996)的是342-CpG模型,用于预测390个细胞系的DTX活性。然而,我们的预测模型采用mRNA表达和突变的组合作为输入变量,与基于cpg的模型相比,准确性较低。290 mRNA/突变模型预测PTX活性的R2为0.830(546个细胞系),236 mRNA/突变模型计算DTX活性的R2为0.751(531个细胞系)。基于cpg的肺癌细胞系模型对PTX (74 CpGs, 88细胞系)和DTX (58 CpGs, 83细胞系)也具有较高的预测能力(R2≥0.980)。紫杉烷活性/抗性背后的潜在分子生物学在这些模型中是显而易见的。事实上,PTX或DTX cpg模型中所代表的许多基因具有与凋亡(例如,ACIN1, TP73, TNFRSF10B, DNASE1, DFFB, CREB1, BNIP3)和有丝分裂/微管(例如,MAD1L1, ANAPC2, EML4, PARP3, CCT6A, JAKMIP1)相关的功能。也有参与表观遗传调控的基因(HDAC4、DNMT3B和组蛋白去甲基化酶KDM4B、KDM4C、KDM2B和KDM7A),以及那些以前从未与紫杉烷活性相关的基因(DIP2C、PTPRN2、TTC23、SHANK2)。总之,完全基于多个CpG位点的甲基化,准确预测紫杉烷在细胞系中的活性是可能的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines.

The microtubule-targeting paclitaxel (PTX) and docetaxel (DTX) are widely used chemotherapeutic agents. However, the dysregulation of apoptotic processes, microtubule-binding proteins, and multi-drug resistance efflux and influx proteins can alter the efficacy of taxane drugs. In this review, we have created multi-CpG linear regression models to predict the activities of PTX and DTX drugs through the integration of publicly available pharmacological and genome-wide molecular profiling datasets generated using hundreds of cancer cell lines of diverse tissue of origin. Our findings indicate that linear regression models based on CpG methylation levels can predict PTX and DTX activities (log-fold change in viability relative to DMSO) with high precision. For example, a 287-CpG model predicts PTX activity at R2 of 0.985 among 399 cell lines. Just as precise (R2=0.996) is a 342-CpG model for predicting DTX activity in 390 cell lines. However, our predictive models, which employ a combination of mRNA expression and mutation as input variables, are less accurate compared to the CpG-based models. While a 290 mRNA/mutation model was able to predict PTX activity with R2 of 0.830 (for 546 cell lines), a 236 mRNA/mutation model could calculate DTX activity at R2 of 0.751 (for 531 cell lines). The CpG-based models restricted to lung cancer cell lines were also highly predictive (R2≥0.980) for PTX (74 CpGs, 88 cell lines) and DTX (58 CpGs, 83 cell lines). The underlying molecular biology behind taxane activity/resistance is evident in these models. Indeed, many of the genes represented in PTX or DTX CpG-based models have functionalities related to apoptosis (e.g., ACIN1, TP73, TNFRSF10B, DNASE1, DFFB, CREB1, BNIP3), and mitosis/microtubules (e.g., MAD1L1, ANAPC2, EML4, PARP3, CCT6A, JAKMIP1). Also represented are genes involved in epigenetic regulation (HDAC4, DNMT3B, and histone demethylases KDM4B, KDM4C, KDM2B, and KDM7A), and those that have never been previously linked to taxane activity (DIP2C, PTPRN2, TTC23, SHANK2). In summary, it is possible to accurately predict taxane activity in cell lines based entirely on methylation at multiple CpG sites.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Cancer Research
Advances in Cancer Research 医学-肿瘤学
CiteScore
10.00
自引率
0.00%
发文量
52
期刊介绍: Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. The first ACR volume came out in the year that Watson and Crick reported on the central dogma of biology, the DNA double helix. In the first 100 volumes are found many contributions by some of those who helped shape the revolution and who made many of the remarkable discoveries in cancer research that have developed from it.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信